Schiavone Panni Alfredo, Falez Franceso, D'Apolito Rocco, Corona Katia, Perisano Carlo, Vasso Michele
Dipartimento Multidisciplinare di Specialità Medico-Chirurgiche e Odontoiatriche, Università degli Studi della Campania Luigi Vanvitelli, Via Luigi De Crecchio 6, 80138, Naples, Italy.
UOC Ortopedia e Traumatologia, Ospedale Santo Spirito in Saxia, ASL Roma 1, Lungotevere in Saxia 1, 00193, Rome, Italy.
Int Orthop. 2017 Jun;41(6):1155-1162. doi: 10.1007/s00264-017-3438-x. Epub 2017 Mar 22.
The purpose of this study was to retrospectively analyse the clinical, functional and radiological outcomes, and the long-term survivorship of the NexGen Legacy Posterior Stabilised (LPS) knee prosthesis (Zimmer Biomet, Warsaw, IN, USA).
Between 1996 and 2001, 197 primary NexGen LPS total knee arthroplasties (TKAs) were implanted by a single surgeon; 132 prostheses in 124 patients with a minimum follow-up of 15 years were included in the study. Surgical procedure and post-operative care were the same for all patients. All patients were assessed through the International Knee Society (IKS) scores and range of motion (ROM). A complete radiological study was performed for all patients. Failure was defined as revision of at least one prosthetic component for any cause.
IKS knee and function scores, as well as ROM and leg alignment, significantly improved at the latest follow-up (p ≤ 0.05). No significant differences were found between fixed- and mobile-bearing groups. Seven implant failures were reported; the implant survival rate (overall) was 94.7% at the latest follow-up.
This study showed optimal survivorship of the NexGen LPS, associated with a significant improvement in overall outcomes at a minimum follow-up of 15 years.
本研究旨在回顾性分析NexGen Legacy后稳定型(LPS)膝关节假体(美国印第安纳州华沙市捷迈邦美公司)的临床、功能和影像学结果以及长期生存率。
1996年至2001年间,由一名外科医生植入了197例初次NexGen LPS全膝关节置换术(TKA);本研究纳入了124例患者的132个假体,这些患者的最短随访时间为15年。所有患者的手术过程和术后护理均相同。通过国际膝关节协会(IKS)评分和活动范围(ROM)对所有患者进行评估。对所有患者进行了完整的影像学研究。失败定义为因任何原因对至少一个假体组件进行翻修。
在最近一次随访时,IKS膝关节和功能评分以及ROM和下肢对线均有显著改善(p≤0.05)。固定平台组和活动平台组之间未发现显著差异。报告了7例植入物失败;在最近一次随访时,植入物总体生存率为94.7%。
本研究表明,NexGen LPS具有最佳的生存率,在最短15年的随访中,总体结果有显著改善。